We are live on ! Find out more
PTPI

Petros Pharmaceuticals
PTPI

Delisted

PTPI was delisted on the 21st of May, 2025.

Back to rankings

16 hedge funds and large institutions have $1.82M invested in Petros Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% less ownership

Funds ownership: 0.04% → 0.03% (-0.01%)

11% less funds holding

Funds holding: 18 → 16 (-2)

39% less capital invested

Capital invested by funds: $3.02M → $1.82M (-$1.19M)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
16
Holders Change
-2
Holders Change %
-11.11%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SC
Shay Capital
New York
+$101K
2
UBS Group
UBS Group
Switzerland
+$6.5K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$5.85K

Top Sellers

Rank Fund Capital Flow
1
NP
NorthRock Partners
Minnesota
-$270K
2
AFAS
Acorn Financial Advisory Services
Virginia
-$157K
3
Citadel Advisors
Citadel Advisors
Florida
-$64.4K
4
VF
Virtu Financial
New York
-$45K
5
Osaic Holdings
Osaic Holdings
Arizona
-$1.95K
Name Holding Trade Value Shares
Change 		Change in
Stake
SC
1
Shay Capital
New York
$555K +$101K +156 +16%
NP
2
NorthRock Partners
Minnesota
$431K -$270K -416 -47%
Vanguard Group
3
Vanguard Group
Pennsylvania
$219K +$5.85K +9 +2%
CM
4
CM Management
Florida
$200K – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$109K -$1.95K -3 -1%
PTP
6
Platform Technology Partners
New York
$88K – – –
EL
7
EMFO LLC
Florida
$56K – – –
Geode Capital Management
8
Geode Capital Management
Massachusetts
$47K – – –
NRS
9
Neville Rodie & Shaw
New York
$44K – – –
BlackRock
10
BlackRock
New York
$38K -$1.3K -2 -3%
Citadel Advisors
11
Citadel Advisors
Florida
$21K -$64.4K -99 -71%
UBS Group
12
UBS Group
Switzerland
$7K +$6.5K +10 +250%
Osaic Holdings
13
Osaic Holdings
Arizona
$4K -$1.95K -3 -30%
Royal Bank of Canada
14
Royal Bank of Canada
Ontario, Canada
$4K – – –
NFSG
15
Newbridge Financial Services Group
Florida
$2K – – –
AFAS
16
Acorn Financial Advisory Services
Virginia
– -$157K -201 Closed
VF
17
Virtu Financial
New York
– -$45K -57 Closed

PTPI Hedge Fund Activity: Q3 2021 in Review

16 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Petros Pharmaceuticals (PTPI) for Q3 2021, worth a combined $1.82M — down 39% from $3.02M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of PTPI and 0 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 3 added.

The largest buyer was Shay Capital, adding an estimated $101K. The largest seller was NorthRock Partners, cutting an estimated $270K.

  • 16 institutional investors held Petros Pharmaceuticals (PTPI) as of Q3 2021, down from 18 in Q2 2021.
  • Funds reported $1.82M of Petros Pharmaceuticals stock for Q3 2021, down 39% quarter-over-quarter.
  • 0 funds opened new Petros Pharmaceuticals positions in Q3 2021 and 2 closed out, a net change of -2 holders.
  • The largest Petros Pharmaceuticals buyer in Q3 2021 was Shay Capital, an estimated $101K added.
  • The largest Petros Pharmaceuticals seller in Q3 2021 was NorthRock Partners, an estimated $270K sold.

Based on aggregated 13F filings for Q3 2021.